# Gastric Cancer Management and Outcomes

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/gastric-cancer-management-and-outcomes/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers represents a comprehensive exploration of gastric cancer, covering topics such as chemotherapy, endoscopic resection, molecular characterization, lymph node dissection, adjuvant and neoadjuvant therapy, clinical practice guidelines, metastatic gastric cancer, and survival analysis. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10696 |
| Works | 690 |

## Topic papers all

Showing 15 of 690.

- [Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer](https://scholariq.org/papers/preoperative-chemoradiotherapy-for-esophageal-or-junctional-cancer/)
- [Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine](https://scholariq.org/papers/adjuvant-chemotherapy-for-gastric-cancer-with-s-1-an-oral-fluoropyrimidine/)
- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Epidemiology of gastric cancer](https://scholariq.org/papers/epidemiology-of-gastric-cancer/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer](https://scholariq.org/papers/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal-junction-cancer/)
- [Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial](https://scholariq.org/papers/surgical-treatment-of-gastric-cancer-15-year-follow-up-results-of-the-randomised/)
- [Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018](https://scholariq.org/papers/burden-and-cost-of-gastrointestinal-liver-and-pancreatic-diseases-in-the-united/)
- [Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer](https://scholariq.org/papers/five-year-outcomes-of-a-randomized-phase-iii-trial-comparing-adjuvant/)
- [Helicobacter pylori Eradication to Prevent Gastric Cancer in a High-Risk Region of China](https://scholariq.org/papers/helicobacter-pylori-eradication-to-prevent-gastric-cancer-in-a-high-risk-region/)
- [Quality Indicators for Colonoscopy](https://scholariq.org/papers/quality-indicators-for-colonoscopy/)
- [Colorectal cancer screening: a global overview of existing programmes](https://scholariq.org/papers/colorectal-cancer-screening-a-global-overview-of-existing-programmes/)
- [Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781](https://scholariq.org/papers/phase-iii-trial-of-trimodality-therapy-with-cisplatin-fluorouracil-radiotherapy/)
- [Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer](https://scholariq.org/papers/chemotherapy-followed-by-surgery-compared-with-surgery-alone-for-localized/)

## Topic primary papers

Showing 15 of 209.

- [Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine](https://scholariq.org/papers/adjuvant-chemotherapy-for-gastric-cancer-with-s-1-an-oral-fluoropyrimidine/)
- [Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-paclitaxel-versus-placebo-plus-paclitaxel-in-patients-with/)
- [Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-monotherapy-for-previously-treated-advanced-gastric-or-gastro/)
- [Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial](https://scholariq.org/papers/surgical-treatment-of-gastric-cancer-15-year-follow-up-results-of-the-randomised/)
- [Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer](https://scholariq.org/papers/five-year-outcomes-of-a-randomized-phase-iii-trial-comparing-adjuvant/)
- [Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline](https://scholariq.org/papers/colorectal-polypectomy-and-endoscopic-mucosal-resection-emr-european-society-of/)
- [Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction](https://scholariq.org/papers/randomized-double-blind-placebo-controlled-phase-iii-trial-of-apatinib-in/)
- [A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video)](https://scholariq.org/papers/a-prospective-multicenter-study-of-1111-colorectal-endoscopic-submucosal/)
- [Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2022](https://scholariq.org/papers/endoscopic-submucosal-dissection-for-superficial-gastrointestinal-lesions/)
- [Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial](https://scholariq.org/papers/morbidity-and-mortality-of-laparoscopic-versus-open-d2-distal-gastrectomy-for/)
- [Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer](https://scholariq.org/papers/effect-of-laparoscopic-vs-open-distal-gastrectomy-on-3-year-disease-free/)
- [The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer](https://scholariq.org/papers/the-keynote-811-trial-of-dual-pd-1-and-her2-blockade-in-her2-positive-gastric/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study](https://scholariq.org/papers/lapatinib-plus-paclitaxel-versus-paclitaxel-alone-in-the-second-line-treatment/)
- [Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype](https://scholariq.org/papers/worldwide-trends-in-gastric-cancer-mortality-1980-2011-with-predictions-to-2015/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.